We have identified several novel membrane targets that are highly enriched in selected tumor tissues, and generated potent and specific mAbs. Drug conjugates of the mAbs have demonstrated robust potency and efficacy in animal models of tumors expressing high levels of the intended targets. The ADCs are being further optimized and characterized for potency, efficacy, and tolerability in vitro and in vivo. We believe that our drug candidates may provide innovative therapeutic approaches for a significant population of cancer patients to current therapies.
